Treats relapsing forms of multiple sclerosis (MS). ANDA 210309, held by Glenmark Pharms Ltd. Dimethyl Fumarate.
As of Nov 16, 2026, ANDA 210309 (Dimethyl Fumarate), held by Glenmark Pharms Ltd, was first approved by FDA on Oct 6, 2020, with 6 approved supplements and 0 published complete response letters.
Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 6, 2020 | Original application | Approved |
| Dimethyl Fumarate120MG · capsule, delayed release;oral | Dimethyl Fumarate | Rx |
| Dimethyl Fumarate240MG · capsule, delayed release;oral | Dimethyl Fumarate | Rx |
| Jan 22, 2025 | Supplement 6Labeling · Standard review | Approved | None posted |
| Feb 8, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 8, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 8, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 8, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 8, 2024 | Supplement 5Labeling · Standard review | Approved | None posted |
| Oct 6, 2020 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters